Sabrina A Assoumou1,2, Samantha M Paniagua2, Benjamin P Linas1,2,3, Jianing Wang2, Jeffrey H Samet3,4,5, Jonathan Hall2, Laura F White6, Curt G Beckwith7,8. 1. Section of Infectious Diseases, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA. 2. Section of Infectious Diseases, Department of Medicine, Boston Medical Center, Boston, Massachusetts, USA. 3. Boston University School of Public Health, Boston, Massachusetts, USA. 4. Section of General Internal Medicine, Department of Medicine, Boston Medical Center, Boston, Massachusetts, USA. 5. Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA. 6. Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, USA. 7. Division of Infectious Diseases, Department of Medicine, Alpert Medical School of Brown University, Providence, Rhode Island, USA. 8. The Miriam Hospital, Providence, Rhode Island, USA.
Abstract
BACKGROUND: A health department survey revealed nearly half employ laboratory-based HIV and HCV testing (LBT) over rapid testing (RT) in nonhospital settings such as drug detoxification centers. LBT has higher sensitivity for acute HIV infection compared to RT but LBT is not point of care and may result in fewer diagnoses due to loss to follow-up before result delivery. METHODS: We conducted a randomized trial comparing real-world case notification of RT (Orasure) vs LBT (HIV Combo Ag/Ab EIA, HCV EIA) for HIV and HCV at a drug detoxification center. Primary outcome was receipt of test results within 2 weeks. RESULTS: Among 341 individuals screened (11/2016-7/2017), 200 met inclusion criteria; 58% injected drugs and 31% shared needles in the previous 6 months. Of the 200 randomized, 98 received RT and 102 LBT. Among all participants, 0.5% were positive for HIV and 48% for HCV; 96% received test results in the RT arm and 42% in the LBT arm (odds ratio, 28.72; 95% confidence interval, 10.27-80.31). Real-world case notification was 95% and 93% for HIV and HCV RT, respectively, compared to 42% for HIV and HCV LBT. CONCLUSIONS: RT has higher real-world case notification than LBT at drug detoxification centers.Clinical trials registration: NCT02869776.
RCT Entities:
BACKGROUND: A health department survey revealed nearly half employ laboratory-based HIV and HCV testing (LBT) over rapid testing (RT) in nonhospital settings such as drug detoxification centers. LBT has higher sensitivity for acute HIV infection compared to RT but LBT is not point of care and may result in fewer diagnoses due to loss to follow-up before result delivery. METHODS: We conducted a randomized trial comparing real-world case notification of RT (Orasure) vs LBT (HIV Combo Ag/Ab EIA, HCV EIA) for HIV and HCV at a drug detoxification center. Primary outcome was receipt of test results within 2 weeks. RESULTS: Among 341 individuals screened (11/2016-7/2017), 200 met inclusion criteria; 58% injected drugs and 31% shared needles in the previous 6 months. Of the 200 randomized, 98 received RT and 102 LBT. Among all participants, 0.5% were positive for HIV and 48% for HCV; 96% received test results in the RT arm and 42% in the LBT arm (odds ratio, 28.72; 95% confidence interval, 10.27-80.31). Real-world case notification was 95% and 93% for HIV and HCV RT, respectively, compared to 42% for HIV and HCV LBT. CONCLUSIONS: RT has higher real-world case notification than LBT at drug detoxification centers.Clinical trials registration: NCT02869776.
Authors: Bryce D Smith; Eyasu Teshale; Amy Jewett; Cindy M Weinbaum; Alan Neaigus; Holly Hagan; Sam M Jenness; Sharon K Melville; Richard Burt; Hanne Thiede; Alia Al-Tayyib; Praveen R Pannala; Iisa W Miles; Alexa M Oster; Amanda Smith; Teresa Finlayson; Kristina E Bowles; Elizabeth A Dinenno Journal: Clin Infect Dis Date: 2011-10 Impact factor: 9.079
Authors: Tanya L Kowalczyk Mullins; Paula K Braverman; Lorah D Dorn; Linda M Kollar; Jessica A Kahn Journal: J Adolesc Health Date: 2009-07-30 Impact factor: 5.012
Authors: Christopher Bentsen; Lisa McLaughlin; Elizabeth Mitchell; Carol Ferrera; Sally Liska; Robert Myers; Sheila Peel; Paul Swenson; Stephane Gadelle; M Kathleen Shriver Journal: J Clin Virol Date: 2011-10-12 Impact factor: 3.168
Authors: Tammy Goodhue; Arthur Kazianis; Barbara G Werner; Tracy Stiles; Barry P Callis; H Dawn Fukuda; Kevin Cranston Journal: J Clin Virol Date: 2013-12 Impact factor: 3.168
Authors: O Falade-Nwulia; S H Mehta; J Lasola; C Latkin; A Niculescu; C O'Connor; P Chaulk; K Ghanem; K R Page; M S Sulkowski; D L Thomas Journal: J Viral Hepat Date: 2016-02-03 Impact factor: 3.728
Authors: Caitlin Conrad; Heather M Bradley; Dita Broz; Swamy Buddha; Erika L Chapman; Romeo R Galang; Daniel Hillman; John Hon; Karen W Hoover; Monita R Patel; Andrea Perez; Philip J Peters; Pam Pontones; Jeremy C Roseberry; Michelle Sandoval; Jessica Shields; Jennifer Walthall; Dorothy Waterhouse; Paul J Weidle; Hsiu Wu; Joan M Duwve Journal: MMWR Morb Mortal Wkly Rep Date: 2015-05-01 Impact factor: 17.586
Authors: Sabrina A Assoumou; Carlos R Sian; Christina M Gebel; Benjamin P Linas; Jeffrey H Samet; Judith A Bernstein Journal: Drug Alcohol Depend Date: 2021-01-11 Impact factor: 4.492
Authors: Sabrina A Assoumou; Samantha M Paniagua; Priscilla Gonzalez; Jianing Wang; Curt G Beckwith; Laura F White; Jessica L Taylor; Kristen Coogan; Jeffrey H Samet; Benjamin P Linas Journal: AIDS Behav Date: 2021-03-22
Authors: Eugene S G Massey; Angela R Bazzi; Carlos R Sian; Christina M Gebel; Judith A Bernstein; Sabrina A Assoumou Journal: AIDS Care Date: 2022-02-02